AVXL
Anavex Life Sciences Corporation
-22.55%
$11.75 - $9.10
Feb 7th 2023 - Mar 21st 2023
Mar, 21, 2023
Anavex's A2-73 Blarcamesine's trial result... See more
Mar, 20, 2023
Complete Results!! !
HEPA
Hepion Pharmaceuticals Inc
-16.85%
$0.86 - $0.72
Feb 7th 2023 - Mar 21st 2023
Mar, 20, 2023
If so, then they must know that the results are go... See more
Feb, 16, 2023
$HEPA from Twitter Madrigal Conference ▶️ $MDGL P... See more
Mar, 21, 2023
Anavex's A2-73 Blarcamesine's trial results on 2 previously completed adult phase-3 trials were highly successful.
Mar, 20, 2023
Complete Results!! !
Mar, 16, 2023
But the company actually has never seen before wonderful results.
Feb, 26, 2023
If results hold up, the stock will achieve massive gains.
Feb, 26, 2023
The results were excellent on the 2 completed adult trials, and because the 3rd trial is pediatric and early on the disease, they are expected to perform even better.
Feb, 14, 2023
Alzheimer's is the most valuable and most difficult indication and most desired lately.. and only Anavex really has some great results with a great safety record. .
Jan, 24, 2023
The sava results trounce you guys 🤦🏻♂️🤦🏻♂️🤦🏻♂️😂😂😂
Jan, 24, 2023
Sava has potential and the phase 3 results will show the truth.
Jan, 24, 2023
Sava has good results. .
Mar, 16, 2023
But the company actually has never seen before wonderful results.
Mar, 9, 2023
And, make no mistake, the result are impressive.
Feb, 1, 2023
It is the best results that have been seen in AD.
Jan, 30, 2023
Overall, results impressive.
Jan, 23, 2023
This could be huge in eliminating artificial FUD against the top-line results.
Jan, 13, 2023
$SAVA Market is moving higher as SAVA is expecting data results.
Jan, 9, 2023
Anavex is late like the sun comes up and still produces great results.
Jan, 7, 2023
MOST IMPORTANTLY, THE RESULTS MUST HAVE BEEN GOOD AND PROMISING at each snapshot that leads Remi to use the word "Thrilled" in Dec 6 PR.
Mar, 20, 2023
If so, then they must know that the results are going to be quite spectacular and market moving.
Feb, 16, 2023
$HEPA from Twitter Madrigal Conference ▶️ $MDGL Per Management For potential Ex-USA partnership-Significant amount of interest and that interest has heightened significantly especially after Ph3 results per CEO!
Feb, 7, 2023
Remarkable results i would say….
Feb, 7, 2023
Yes very very interesting results.
Jan, 11, 2023
The 28 day data also documented Rencofilstat’s amazingly fast & potent efficacy at reduction of fibrosis that in just 4 short weeks exceeded that of Madrigal’s 12 month hospitalization IV dosage results for their drug used in NASH.
Jan, 9, 2023
I didnt sell a share and with stellar results for this soon to be released study it should gain traction well over 3 imo.
Jan, 9, 2023
Brilliant move or some stellar early results.
Jan, 9, 2023
• Treatment with RCF for 28 days results in a reduction in ceramides, free fatty acids, and triglycerides suggestive of a therapeutic benefit.
Dec, 28, 2022
We knows recession is coming next year 4) XBI has bottomed and should begin its upward move next year 5) Phase 2b trial results and updates on HCC trial 6) Probable approvals of NASH drugs and increased bullish sentiment in the sector
Dec, 19, 2022
button for good trial results in the NASH space.